Obermatt
See Similar Stocks →

InterCure

TLV:INCR · IL0011063760
PharmaceuticalsSmall

360

22
Medium confidence — indicative
Profit price75
Owner Earnings Yield1
Dividend Yield1
Price/Sales97
EV / Gross Profit18
Price/Book97
Return on Capital37
Cash Return on Capital41
Return on Equity44
EBIT Margin10
Gross Profitability15
Accruals64
Owner Earnings Margin25
Sales growth88
Profit growth15
Reinvestment86
Price momentum12
Debt load38
Refinancing96
Debt Payback1
Liquidity18
Analyst ratings68
Expectations trend50
Market mood46
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

InterCure doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryIsrael
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTASE
Founded1994
Employees14
Websiteintercure.co
ISINIL0011063760
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
CannabisAlternative MedicineBiotechnologyHealth CareManufacturingMedical DeviceTherapeutics

Description

InterCure Ltd. operates in the medical cannabis sector. The company owns all of the issued and outstanding shares of Canndoc (Canndoc Ltd.), Pharmazone (Pharmazone Ltd.), and Cannolam (Cannolam Ltd.); and other holdings in additional pharmacies and…

Analysis

Middle-of-the-road

InterCure Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is mixed; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
48
2023202420252026

All-time high

88

Jan 2023

All-time low

23

Mar 2026

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
97
71
94
60
Price/Earnings
62
61
91
46
Price/Book
97
87
90
65
Dividend Yield
1
1
1
1
Value (overall)
75
76
87
38

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare InterCure with its peers
PolyPid
NAQ:PYPD
26
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Pharvaris
NSQ:PHVS
38
CountryNetherlands
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Oculis Holding
NMQ:OCS
18
CountrySwitzerland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Mediwound
NMQ:MDWD
25
CountryIsrael
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Lavipharm
ATH:LAVI
44
CountryLuxembourg
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Haleon
LSE:HLN
31
CountryUK
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →